⌘K
t
Solvonis Therapeutics plc confirmed its total voting rights as at 31 July 2025. The company's issued share capital comprises 6,262,104,024 Ordinary Shares, each with one voting right, and it holds no Ordinary Shares in treasury.
| Date | 31 Jul 2025 |
| Time | 16:30:00 |
| Category | Capital structure |
| ID | 2497T |
("Solvonis" or the "Company")
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, confirms that the Company's issued share capital as at the date of this announcement comprises 6,262,104,024 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 6,262,104,024.
The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.
Enquiries:
|
Solvonis Therapeutics plc |
anthony@solvonis.com |
|
Anthony Tennyson, CEO & Executive Director |
|
|
|
|
|
Allenby Capital Limited (Financial Adviser and Joint Broker) |
+44 (0) 20 3328 5656 |
|
Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance) Guy McDougall (Sales & Corporate Broking) |
|
|
|
|
|
Singer Capital Markets (Joint Broker) |
+44(0) 20 7496 3000 |
|
Phil Davies |
|